Skip to main content
NCD 190.18 · version 1 · Laboratory NCD

NCD 190.18: Serum Iron Studies

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.18

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
3,279 covered ICD-10
233 non-covered

TL;DR

NCD 190.18 sets Medicare's national policy for serum iron studies under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. • Ferritin, iron and either iron binding capacity or transferrin are useful in the differential diagnosis of iron deficiency, anemia, and for iron overload conditions. As a laboratory NCD it carries a national ICD-10 edit list: 3,279 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 4 procedure codes.

Item or service described

Serum iron studies are useful in the evaluation of disorders of iron metabolism, particularly iron deficiency and iron excess. Iron studies are best performed when the patient is fasting in the morning and has abstained from medications that may influence iron balance.

Iron deficiency is the most common cause of anemia. In young children on a milk diet, iron deficiency is often secondary to dietary deficiency. In adults, iron deficiency is usually the result of blood loss and is only occasionally secondary to dietary deficiency or malabsorption.

Following major surgery the patient may have iron deficient erythropoiesis for months or years if adequate iron replacement has not been given. High doses of supplemental iron may cause the serum iron to be elevated. Serum iron may also be altered in acute and chronic inflammatory and neoplastic conditions.

Total iron binding capacity (TIBC) is an indirect measure of transferrin, a protein that binds and transports iron. TIBC quantifies transferrin by the amount of iron that it can bind. TIBC and transferrin are elevated in iron deficiency, and with oral contraceptive use, and during pregnancy. TIBC and transferrin may be decreased in malabsorption syndromes or in those affected with chronic diseases. The percent saturation represents the ratio of iron to the TIBC.

Assays for ferritin are also useful in assessing iron balance. Low concentrations are associated with iron deficiency and are highly specific. High concentrations are found in hemosiderosis (iron overload without associated tissue injury) and hemochromatosis (iron overload with associated tissue injury). In these conditions the iron is elevated, the TIBC and transferrin are within the reference range or low, and the percent saturation is elevated. Serum ferritin can be useful for both initiating and monitoring treatment for iron overload.

Transferrin and ferritin belong to a group of serum proteins known as acute phase reactants, and are increased in response to stressful or inflammatory conditions and also can occur with infection and tissue injury due to surgery, trauma or necrosis. Ferritin and iron/TIBC (or transferrin) are affected by acute and chronic inflammatory conditions, and in patients with these disorders, tests of iron status may be difficult to interpret.

Indications and limitations of coverage

Indications

• Ferritin, iron and either iron binding capacity or transferrin are useful in the differential diagnosis of iron deficiency, anemia, and for iron overload conditions.

• The following presentations are examples that may support the use of these studies for evaluating iron deficiency: certain abnormal blood count values (i.e., decreased mean corpuscular volume (MCV), decreased hemoglobin/hematocrit when the MCV is low or normal, or increased red cell distribution width (RDW) and low or normal MCV); abnormal appetite (pica); acute or chronic gastrointestinal blood loss; hematuria; menorrhagia; malabsorption; status post-gastrectomy; status post-gastrojejunostomy; malnutrition; preoperative autologous blood collection(s); malignant, chronic inflammatory and infectious conditions associated with anemia which may present in a similar manner to iron deficiency anemia; following a significant surgical procedure where blood loss had occurred and had not been repaired with adequate iron replacement.

• The following presentations are examples that may support the use of these studies for evaluating iron overload: chronic hepatitis; diabetes;

hyperpigmentation of skin; arthropathy; cirrhosis; hypogonadism; hypopituitarism; impaired porphyrin metabolism; heart failure; multiple transfusions; sideroblastic anemia; thalassemia major; cardiomyopathy, cardiac dysrhythmias and conduction disturbances.

• Follow-up testing may be appropriate to monitor response to therapy, e.g., oral or parenteral iron, ascorbic acid, and erythropoietin.

• Iron studies may be appropriate in patients after treatment for other nutritional deficiency anemias, such as folate and vitamin B12, because iron deficiency may not be revealed until such a nutritional deficiency is treated.

• Serum ferritin may be appropriate for monitoring iron status in patients with chronic renal disease with or without dialysis.

• Serum iron may also be indicated for evaluation of toxic effects of iron and other metals (e.g., nickel, cadmium, aluminum, lead) whether due to accidental, intentional exposure or metabolic causes.

Limitations

• Iron studies should be used to diagnose and manage iron deficiency or iron overload states. These tests are not to be used solely to assess acute phase reactants where disease management will be unchanged. For example, infections and malignancies are associated with elevations in acute phase reactants such as ferritin, and decreases in serum iron concentration, but iron studies would only be medically necessary if results of iron studies might alter the management of the primary diagnosis or might warrant direct treatment of an iron disorder or condition.

• If a normal serum ferritin level is documented, repeat testing would not ordinarily be medically necessary unless there is a change in the patient's condition, and ferritin assessment is needed for the ongoing management of the patient. For example, a patient presents with new onset insulin-dependent diabetes mellitus and has a serum ferritin level performed for the suspicion of hemochromatosis. If the ferritin level is normal, the repeat ferritin for diabetes mellitus would not be medically necessary.

• When an End Stage Renal Disease (ESRD) patient is tested for ferritin, testing more frequently than every three months requires documentation of medical necessity (e.g., other than chronic renal failure or renal failure, unspecified).

• It is ordinarily not necessary to measure both transferrin and TIBC at the same time because TIBC is an indirect measure of transferrin. When transferrin is ordered as part of the nutritional assessment for evaluating malnutrition, it is not necessary to order other iron studies unless iron deficiency or iron overload is suspected as well.

• It is not ordinarily necessary to measure both iron/TIBC (or transferrin) and ferritin in initial patient testing. If clinically indicated after evaluation of the initial iron studies, it may be appropriate to perform additional iron studies either on the initial specimen or on a subsequently obtained specimen. After a diagnosis of iron deficiency or iron overload is established, either iron/TIBC (or transferrin) or ferritin may be medically necessary for monitoring, but not both.

• It would not ordinarily be considered medically necessary to do a ferritin as a preoperative test except in the presence of anemia or recent autologous blood collections prior to the surgery.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.18 version 1. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 3,279 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

4 procedure codes are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.18
CodeCode set
82728CPT (descriptor licensed by AMA)
83540CPT (descriptor licensed by AMA)
83550CPT (descriptor licensed by AMA)
84466CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 4 of the 4 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $6.47 to $13.63, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.18 edits, October 2026
CodeCLFS amountWith QWPricing
82728$13.63—national payment amount
83540$6.47—national payment amount
83550$8.74—national payment amount
84466$12.76—national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 3,279 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.18 (sample)
ICD-10-CMDescriptionEffective
A01.00Typhoid fever, unspecified2015-10-01
A01.01Typhoid meningitis2015-10-01
A01.02Typhoid fever with heart involvement2015-10-01
A01.03Typhoid pneumonia2015-10-01
A01.04Typhoid arthritis2015-10-01
A01.05Typhoid osteomyelitis2015-10-01
A01.09Typhoid fever with other complications2015-10-01
A01.1Paratyphoid fever A2015-10-01
A01.2Paratyphoid fever B2015-10-01
A01.3Paratyphoid fever C2015-10-01
A01.4Paratyphoid fever, unspecified2015-10-01
A02.0Salmonella enteritis2015-10-01
A02.1Salmonella sepsis2015-10-01
A02.20Localized salmonella infection, unspecified2015-10-01
A02.21Salmonella meningitis2015-10-01
A02.22Salmonella pneumonia2015-10-01
A02.23Salmonella arthritis2015-10-01
A02.24Salmonella osteomyelitis2015-10-01
A02.25Salmonella pyelonephritis2015-10-01
A02.29Salmonella with other localized infection2015-10-01
A02.8Other specified salmonella infections2015-10-01
A02.9Salmonella infection, unspecified2015-10-01
A04.0Enteropathogenic Escherichia coli infection2015-10-01
A04.1Enterotoxigenic Escherichia coli infection2015-10-01
A04.2Enteroinvasive Escherichia coli infection2015-10-01
A04.3Enterohemorrhagic Escherichia coli infection2015-10-01
A04.4Other intestinal Escherichia coli infections2015-10-01
A04.5Campylobacter enteritis2015-10-01
A04.6Enteritis due to Yersinia enterocolitica2015-10-01
A04.71Enterocolitis due to Clostridium difficile, recurrent2017-10-01
A04.72Enterocolitis due to Clostridium difficile, not specified as recurrent2017-10-01
A04.8Other specified bacterial intestinal infections2015-10-01
A04.9Bacterial intestinal infection, unspecified2015-10-01
A06.0Acute amebic dysentery2015-10-01
A06.1Chronic intestinal amebiasis2015-10-01
A06.2Amebic nondysenteric colitis2015-10-01
A06.3Ameboma of intestine2015-10-01
A06.4Amebic liver abscess2015-10-01
A06.5Amebic lung abscess2015-10-01
A06.6Amebic brain abscess2015-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.18 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 10 codes added and 5 codes removed against January 2026. CMS marked 10 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.

ICD-10-CM codes added to NCD 190.18 in October 2026
ICD-10-CMFY2027 descriptionResult
D69.11Glanzmann thrombastheniacovered
D69.19Other qualitative platelet defectscovered
I42.00Dilated cardiomyopathy, unspecifiedcovered
I42.01Familial-genetic dilated cardiomyopathycovered
I42.09Other dilated cardiomyopathycovered
I42.81Arrhythmogenic cardiomyopathycovered
I42.89Other cardiomyopathies not elsewhere classifiedcovered
I49.81Brugada syndromecovered
I49.82Ventricular bigeminycovered
I49.89Other specified cardiac arrhythmias not elsewhere classifiedcovered
ICD-10-CM codes removed from NCD 190.18 in October 2026
ICD-10-CMDescriptionWasWhy
C75.9Malignant neoplasm of endocrine gland, unspecifiedcoveredterm-dated 2026-09-30; code still valid
D69.1Qualitative platelet defectscovereddeleted from ICD-10-CM; replaced by D69.11, D69.19
I42.0Dilated cardiomyopathycovereddeleted from ICD-10-CM; replaced by I42.00, I42.01, I42.09
I42.8Other cardiomyopathiescovereddeleted from ICD-10-CM; replaced by I42.81, I42.89
I49.8Other specified cardiac arrhythmiascovereddeleted from ICD-10-CM; replaced by G90.A, I49.81, I49.82, I49.89

Codes on this NCD's list by release: October 2025: 3,497 · January 2026: 3,507 · October 2026: 3,512. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links one analysis to NCD 190.18, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00263R Serum Iron Studies (Addition of Restless Leg Syndrome as a Covered Indication) (1st Recon, Closed)

Revision history

12/2019 - Changes to the Laboratory National Coverage Determination (NCD) Edit Software for April 2020. This Change Request (CR) announces the changes that will be included in the April 2020 quarterly release of the edit module for clinical diagnostic laboratory services. This recurring update notification applies to chapter 16, section 120.2, publication 100-04. ( TN 4475 ) (CR11593)

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.18

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.18

What does NCD 190.18 cover?

• Ferritin, iron and either iron binding capacity or transferrin are useful in the differential diagnosis of iron deficiency, anemia, and for iron overload conditions. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.18 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.18?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.18?

The October 2026 laboratory NCD edit list contains 3,279 ICD-10-CM codes that support serum iron studies (for example A01.00 Typhoid fever, unspecified; A01.01 Typhoid meningitis; A01.02 Typhoid fever with heart involvement) and 233 codes that deny. The list applies to 82728, 83540, 83550, 84466.

How often does the lab NCD code list for 190.18 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.